Phase I/II Investigation of Temsirolimus Plus Lenalidomide in Relapsed Non-Hodgkin Lymphomas.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 27 Oct 2017
At a glance
- Drugs Lenalidomide (Primary) ; Temsirolimus (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Hodgkin's disease; Lymphoma; Non-Hodgkin's lymphoma; T cell lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; Therapeutic Use
- 24 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 24 Jun 2016 Planned primary completion date changed from 1 May 2016 to 1 Dec 2016.
- 17 May 2015 Planned primary completion date changed from 1 Jun 2015 to 1 May 2016 as reported by ClinicalTrials.gov